Literature DB >> 24393558

Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.

Sam Harirforoosh1, Waheed Asghar, Fakhreddin Jamali.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are used chronically to reduce pain and inflammation in patients with arthritic conditions, and also acutely as analgesics by many patients. Both therapeutic and adverse effects of NSAIDs are due to inhibition of cyclooxygenase (COX) enzyme. NSAIDs are classified as non-selective and COX-2-selective inhibitors (COXIBS) based on their extent of selectivity for COX inhibition. However, regardless of their COX selectivity, reports are still appearing on the GI side effect of NSAIDs particularly on the lower gastrointestinal (GI) tract and the harmful role of their controlled release formulations. In addition, previously unpublished data stored in the sponsor's files, question the GI sparing properties of rofecoxib, a COXIB that has been withdrawn due to cardiovascular (CV) side effects. Presently, the major side effects of NSAIDs are the GI complications, renal disturbances and CV events. There is a tendency to believe that all NSAIDs are associated with renal and CV side effects, a belief that is not supported by solid evidence. Indeed, lower but still therapeutics doses of some NSAIDs may be cardioprotective. In this review, we briefly discuss the GI toxicity of the NSAIDs and assess their renal and CV adverse effects in more detail.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24393558     DOI: 10.18433/j3vw2f

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  165 in total

1.  Dietary apigenin reduces LPS-induced expression of miR-155 restoring immune balance during inflammation.

Authors:  Daniel Arango; Mayra Diosa-Toro; Laura S Rojas-Hernandez; Jessica L Cooperstone; Steven J Schwartz; Xiaokui Mo; Jinmai Jiang; Thomas D Schmittgen; Andrea I Doseff
Journal:  Mol Nutr Food Res       Date:  2015-02-23       Impact factor: 5.914

2.  Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.

Authors:  Michael E Rothenberg; Michael Tagen; Jae H Chang; Janel Boyce-Rustay; Michel Friesenhahn; David H Hackos; Avis Hains; Dan Sutherlin; Michael Ward; William Cho
Journal:  Clin Drug Investig       Date:  2019-09       Impact factor: 2.859

3.  Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis.

Authors:  Waheed Asghar; Ali Aghazadeh-Habashi; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2017-04-07       Impact factor: 4.473

4.  A retrospective study of proteinuria in dogs receiving toceranib phosphate.

Authors:  Sindy L Piscoya; Kelly R Hume; Cheryl E Balkman
Journal:  Can Vet J       Date:  2018-06       Impact factor: 1.008

5.  Nonsteroidal Anti-Inflammatory Drugs and Risk of First Hospitalization for Heart Failure in Patients with No History of Heart Failure: A Population-Based Case-Crossover Study.

Authors:  Sung-Po Huang; Yao-Chun Wen; Shih-Tsung Huang; Chih-Wan Lin; Tzung-Dau Wang; Fei-Yuan Hsiao
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

6.  Role of cannabinoid receptor 1 and the peroxisome proliferator-activated receptor α in mediating anti-nociceptive effects of synthetic cannabinoids and a cannabinoid-like compound.

Authors:  Mohammad Alsalem; Mansour Haddad; Sara A Aldossary; Heba Kalbouneh; Ahmad Altarifi; Sahar M Jaffal; Manal A Abbas; Nour Aldaoud; Khalid El-Salem
Journal:  Inflammopharmacology       Date:  2019-04-03       Impact factor: 4.473

7.  Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain.

Authors:  Yuri Kato; Miki Hiasa; Reiko Ichikawa; Nao Hasuzawa; Atsushi Kadowaki; Ken Iwatsuki; Kazuhiro Shima; Yasuo Endo; Yoshiro Kitahara; Tsuyoshi Inoue; Masatoshi Nomura; Hiroshi Omote; Yoshinori Moriyama; Takaaki Miyaji
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

8.  Molecular docking and pharmacological/toxicological assessment of a new compound designed from celecoxib and paracetamol by molecular hybridization.

Authors:  Daiany P B da Silva; Iziara F Florentino; Dayane M da Silva; Roberta C Lino; Carina S Cardoso; Lorrane K S Moreira; Géssica A Vasconcelos; Daniela C Vinhal; Anna C D Cardoso; Bianca Villavicencio; Hugo Verli; Boniek G Vaz; Luciano M Lião; Luiz C da Cunha; Ricardo Menegatti; Elson A Costa
Journal:  Inflammopharmacology       Date:  2018-07-23       Impact factor: 4.473

9.  Increased expression of tight junction protein occludin is associated with the protective effect of mosapride against aspirin-induced gastric injury.

Authors:  Chenchen Liu; Zhaotao Duan; Yue Guan; Hailu Wu; Kewei Hu; Xin Gao; Fangcen Yuan; Zongdan Jiang; Ye Fan; Bangshun He; Shukui Wang; Zhenyu Zhang
Journal:  Exp Ther Med       Date:  2017-11-23       Impact factor: 2.447

Review 10.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.